Search Results

Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, marking the pharmaceutical giant's entry into the rapidly evolving psychedelic therapeutics market. The acquisition strengthens Lilly's neuroscience portfolio with a pipeline of late-stage psychedelic-based therapies aimed at treatment-resistant depression (TRD), major depressive disorder (MDD) and other difficult-to-treat psychiatric conditions. The transaction is expected to close during the third quarter of 2026. Lilly Expands Neuroscience Portfolio Through AtaiBeckley Acquisition Under the agreement, Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, valuing the company at approximately $2.8 billion. Shareholders will also be eligible to receive a contingent value right (CVR) worth $2.50 per share, representing around $1 billion in additional milestone payments linked to the clinical and regulatory progress of the company's lead psychedelic programmes. The acquisition follows months of industry speculation that Lilly was evaluating opportunities within the psychedelic medicine sector. BPL-003 Leads AtaiBeckley's Psychedelic Pipeline The centrepiece of the acquisition is BPL-003, an intranasal formulation of mebufotenin benzoate currently being developed for treatment-resistant depression. The therapy recently achieved both primary and secondary endpoints in a Phase IIb clinical trial, with a global Phase III programme already underway. Lilly will also acquire VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT), which is expected to enter late-stage clinical development for major depressive disorder. A third pipeline candidate, EMP-01, is an oral formulation of R-MDMA being investigated as a treatment for social anxiety disorder. Together, the portfolio provides Lilly with multiple late-stage assets targeting significant unmet needs across psychiatry. Psychedelic Medicines Continue to Gain Pharmaceutical Momentum The acquisition reflects growing pharmaceutical confidence in psychedelic-based medicines as a new generation of treatments for neuropsychiatric disorders. Interest in the sector has accelerated following the commercial success of Johnson & Johnson's Spravato (esketamine), while several other companies continue advancing psychedelic therapies through late-stage development. Industry momentum has also been supported by regulatory initiatives designed to accelerate the development of innovative treatments for severe mental health conditions. Why the Deal Matters Treatment-resistant depression remains one of the largest unmet needs in mental healthcare, with many patients failing to respond adequately to conventional antidepressants. Rapid-acting psychedelic therapies are being investigated as potential alternatives capable of producing faster and more durable clinical responses through novel mechanisms of action. By acquiring AtaiBeckley, Lilly gains immediate access to a differentiated pipeline without the lengthy timelines associated with early-stage drug discovery. The transaction also expands Lilly's position in neuroscience beyond traditional psychiatric medicines into one of the fastest-growing areas of pharmaceutical innovation. Executive Commentary Lilly Neuroscience President Carole Ho said the acquisition reflects the company's commitment to addressing difficult-to-treat mental health conditions. "Treatment-resistant depression persists even after multiple treatments have failed. Advancing AtaiBeckley's investigational therapies gives us a real chance to change that." Analysts have also highlighted the strategic importance of the acquisition, noting that the deal broadens Lilly's neuroscience portfolio while positioning the company at the forefront of next-generation psychiatric drug development. Outlook The acquisition represents another significant vote of confidence in psychedelic therapeutics from a major pharmaceutical company. With BPL-003 already entering Phase III development and additional candidates progressing towards late-stage studies, Lilly is positioning itself to become a major player in the future treatment landscape for depression and other serious psychiatric disorders. As clinical evidence continues to mature, the deal highlights how large pharmaceutical companies are increasingly turning to innovative neuroscience platforms to address some of the most challenging areas of medicine. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Oral cholesterol therapy offers an alternative to injectable PCSK9 inhibitors as Merck targets multi-billion-dollar cardiovascular market. Merck & Co. (MSD) has secured US Food and Drug Administration (FDA) approval for Lipfendra (enlicitide), making it the first once-daily oral PCSK9 inhibitor approved in the US for lowering low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH). The approval marks a significant milestone in the cholesterol treatment landscape, introducing an oral alternative to injectable PCSK9 inhibitors that have transformed LDL-C management over the past decade. First Oral PCSK9 Inhibitor Approved in the US Lipfendra is indicated for adults with hypercholesterolaemia, including patients with HeFH, and works by inhibiting PCSK9, a protein involved in regulating LDL cholesterol levels. Unlike existing PCSK9 therapies, which require injections every two weeks or monthly, Lipfendra is administered as a once-daily tablet, potentially offering greater convenience for patients and expanding access to this class of cholesterol-lowering medicines. Dean Y. Li, President of Merck Research Laboratories, described the approval as a pivotal moment, saying the drug provides patients with an important new treatment option. Phase III Trials Demonstrated Significant LDL-C Reduction The FDA approval was supported by data from two Phase III clinical trials: CORALreef Lipids CORALreef HeFH In the CORALreef HeFH study, Lipfendra achieved approximately 59% LDL-C reduction versus placebo in patients with heterozygous familial hypercholesterolaemia. Meanwhile, the CORALreef Lipids trial demonstrated an almost 56% reduction in LDL-C among patients with atherosclerotic cardiovascular disease (ASCVD). Merck is also conducting a cardiovascular outcomes study to determine whether LDL-C reductions translate into lower rates of heart attacks, strokes and cardiovascular death. Challenging the Injectable PCSK9 Market The PCSK9 inhibitor market has traditionally been dominated by injectable biologics, including: Amgen's Repatha (evolocumab) Sanofi and Regeneron's Praluent (alirocumab) While these medicines have demonstrated strong efficacy, injectable administration has been viewed as a barrier for some patients. Lipfendra's oral formulation could broaden use of PCSK9 inhibition, particularly within primary care settings where physicians may favour a tablet over injectable therapy. Pricing also appears central to Merck's commercial strategy. Lipfendra will launch with a list price of approximately $315 per month, substantially below the typical $500–600 monthly cost of existing injectable PCSK9 inhibitors. Analysts believe this pricing strategy could accelerate adoption and expand the overall market rather than simply compete for existing patients. Strategic Importance for Merck Lipfendra represents one of Merck's most important late-stage pipeline assets as the company prepares for the eventual loss of exclusivity of blockbuster immunotherapy Keytruda (pembrolizumab) in 2028. The company has identified several pipeline medicines expected to drive future growth, with Lipfendra viewed as a potential multi-billion-dollar product. Analysts suggest that widespread uptake among primary care physicians could generate peak annual sales approaching $5bn, particularly if oral therapy encourages earlier use of PCSK9 inhibition in cholesterol management. Competition Continues to Build Although Lipfendra is the first oral PCSK9 inhibitor to reach the market, competition is already emerging. AstraZeneca is developing AZD0780, an investigational oral PCSK9 inhibitor that has demonstrated nearly 51% LDL-C reduction in mid-stage studies. One potential differentiator may be dosing convenience. Lipfendra must be taken on an empty stomach, with patients required to wait at least 30 minutes before eating, while AstraZeneca's candidate has not demonstrated the same fasting requirement. As oral PCSK9 therapies enter clinical practice, convenience, pricing and long-term cardiovascular outcomes are likely to become key differentiators. Outlook The approval of Lipfendra introduces the first oral PCSK9 inhibitor into clinical practice and could reshape the treatment landscape for patients requiring intensive LDL-C lowering. By combining efficacy comparable to injectable therapies with oral administration and competitive pricing, Merck is positioning Lipfendra to expand adoption of PCSK9 inhibition beyond specialist care. With cardiovascular outcomes data still to come and additional oral competitors in development, the approval represents the beginning of a new phase in cholesterol management rather than the end of the story. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Series B financing gives Crystalys additional capital to progress its late-stage clinical programme and prepare dotinurad for potential commercialisation. Crystalys Therapeutics has closed an oversubscribed $130 million Series B financing led by Frazier Life Sciences to support the global late-stage development and commercialisation preparation of dotinurad for gout. The investment extends support for two registration-directed Phase 3 trials and a Phase 2 study as the company works towards further clinical, regulatory and commercial-readiness milestones. Field Content Alert Type Deal Companies Crystalys Therapeutics; financing led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund and existing investors. Deal Type Series B financing Asset or Company Crystalys Therapeutics and its lead candidate, dotinurad Therapy Area(s) Rheumatology; gout Technology or Modality Once-daily oral URAT1 inhibitor Deal Value $130 million in closed Series B financing. Development Stage Phase 3, with two registration-directed studies underway; an additional Phase 2 study is also ongoing. Geography Global clinical development and commercialisation preparation What Happened Crystalys closed an oversubscribed $130 million Series B round led by Frazier Life Sciences. The proceeds will support the RUBY and TOPAZ Phase 3 trials, the Phase 2 AMETHYST study, commercialisation preparation and the company’s operational runway through anticipated clinical and regulatory milestones. Why It Matters The financing provides Crystalys with additional resources to progress dotinurad across a broad gout-development programme while preparing the company for potential regulatory submissions and commercialisation. It also supports continued development of a possible second-line option for patients inadequately served by existing urate-lowering treatments. Supporting Context Dotinurad is already approved in Japan, China, the Philippines, Taiwan and Thailand. Crystalys is developing it as a potential second-line therapy intended to reduce uric acid, gout flares and tophi. Key Takeaway The $130 million financing gives Crystalys further runway to move dotinurad through late-stage development and towards commercial readiness. What to Watch Results from the RUBY, TOPAZ and AMETHYST studies and any subsequent clinical, regulatory or commercialisation milestones. Primary Source Crystalys Therapeutics’ official financing announcement Relevant Date 22 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Assessing cardiology training programmes and their role in improving professional competency. Cardiology remains one of the most data-intensive and guideline-driven therapy areas, making high-quality education essential. To assess the effectiveness of cardiology education, nuaxia analysed behavioural data from cardiology-focused learning activities. This analysis evaluates changes in healthcare professionals' knowledge and competence before and after educational interventions, providing clear evidence of how cardiology education supports learning and clinical confidence. Key Findings at a Glance 90% of Participants Improved Their Scores 90% of HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 47% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 47% improved 45% remained stable Only 8% saw a decrease This shift underlines how well-structured education meets HCPs where they are and helps them grow, regardless of the starting point. 30% Achieved the Top Score After Medical Education Activity Importantly, 30% of participants progressed to the top performance group, demonstrating that CME activities are driving measurable improvements in HCP knowledge and competence. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.0%) or Average (27.5%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (50.0%) or Top (30.0%) categories. This demonstrates that medical education’s power lies not just in teaching, but in transforming practice. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This benefits not only HCPs but ultimately improves patient outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Examining the impact of dermatology education on knowledge application and patient care quality. Dermatology education must address a broad spectrum of conditions, from chronic inflammatory diseases to complex diagnostic challenges. nuaxia analysed behavioural data from dermatology-focused medical education activities to evaluate how effectively these programmes support healthcare professional learning. By assessing changes in knowledge and competence following educational interventions, this analysis offers objective insights into the value of dermatology education and its role in improving clinical understanding. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 79% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 79% improved 19% remained stable Only 2% saw a decrease This highlights how education programmes can support HCPs’ growth, regardless of their initial level of knowledge or experience. 44% Achieved the Top Score After Medical Education Activity 44% of participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (51.6%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (43.5%) or High (40.4%) categories. The results underscore that medical education’s true value lies in its ability to change behaviour and outcomes, not just impart information. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This advancement for HCPs directly contributes to better healthcare outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Key findings from neurology education activities and their influence on learning outcomes. Neurology presents unique educational challenges, with intricate disease pathways and rapidly expanding treatment options. To understand how education supports learning in this area, nuaxia analysed behavioural data from neurology-focused medical education activities. This analysis examines changes in knowledge and competence among healthcare professionals, using objective data to uncover how neurology education influences learning outcomes and supports more confident clinical practice. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 71% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 71% improved 28% remained stable Only 1% saw a decrease This reflects how thoughtfully designed CME can meet HCPs where they begin and help them achieve their full potential. 48% Achieved the Top Score After Medical Education Activity Almost half of the participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.9%) or Average (38.8%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (48.2%) or High (44.2%) categories. This proves that impactful CME equips HCPs to move from knowledge to action. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change By supporting HCP development, these educational programmes drive positive change in patient outcomes across the globe. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Insights into oncology learning programmes and their impact on clinical practice and patient care. Oncology is one of the most complex and rapidly advancing areas of medicine, demanding continuous learning from healthcare professionals. But how effective is oncology education in keeping pace with this change? nuaxia analysed extensive behavioural data from oncology-focused educational activities to evaluate how learning interventions support knowledge and competence development. Through sophisticated data science methods, nuaxia measured changes in learning outcomes across oncology education programmes. This analysis provides evidence-based insights into the effectiveness of oncology education, highlighting its role in supporting informed clinical decision-making. Key Findings at a Glance 92% of Participants Improved Their Scores With 92% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 70% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 70% improved 26% remained stable Only 4% saw a decrease These findings highlight how well-designed CME meets learners where they are and guides them toward higher competence. 33% Achieved the Top Score After Medical Education Activity Importantly, a third of participants progressed to the top performance group, highlighting the role of CME in enabling HCPs to achieve higher levels of performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (45.7%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (48.5%) or Top (32.7%) categories. The data confirms that meaningful education in healthcare doesn’t just inform, it shapes practice. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The impact extends beyond healthcare professionals, enhancing care for patients around the globe. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Evaluating the effectiveness of endocrinology learning interventions to support better clinical practice. Endocrinology requires ongoing education to keep pace with evolving treatment guidelines and long-term disease management strategies. But how effective is endocrinology-focused education in driving meaningful learning outcomes? nuaxia analysed behavioural data from endocrinology education activities to answer this question. Through detailed pre- and post-education analysis, nuaxia assessed changes in knowledge and competence, providing data-backed insights into the real-world impact of endocrinology education programmes. Key Findings at a Glance 87% of Participants Improved Their Scores Nearly nine out of ten participants showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 63% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 63% improved 25% remained stable Only 12% saw a decrease These insights show that personalised, structured education enables HCPs to progress meaningfully from any starting point. 32% Achieved the Top Score After Medical Education Activity Nearly a third of participants reached the top performance group, highlighting the effectiveness of CME activities in supporting HCP learning. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (42.7%) or High (42.7%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (46.5%) or Top (32.0%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The benefits reach far beyond learners, fostering measurable improvements in global patient care. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Analysing how targeted haematology training enhances understanding and informs treatment decisions. Haematology education plays a vital role in supporting healthcare professionals managing complex and often life-threatening conditions. But how effective are current educational approaches in this field? nuaxia analysed behavioural data from haematology-focused education activities to evaluate their impact on learner knowledge and competence. Using data-driven methodologies, this analysis tracks changes in learning outcomes before and after educational interventions, providing robust evidence of how haematology education contributes to improved understanding and professional development. Key Findings at a Glance 93% of Participants Improved Their Scores With 93% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 72% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 72% improved 23% remained stable Only 5% saw a decrease The results underline how effective education accommodates diverse learning levels and fosters ongoing growth. 36% Achieved the Top Score After Medical Education Activity Over a third of participants progressed to the top performance group, underscoring the measurable impact of CME on professional learning outcomes. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (41.5%) or Average (39.2%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.5%) or Top (36.6%) categories. These findings illustrate that education in medicine is not merely informative; it inspires measurable improvements. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change These gains for HCPs ultimately translate into higher-quality care for patients worldwide. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Quantifying How Baseline Knowledge Influences Learning Gains in Medical Education Medical education builds on what learners already know, and initial knowledge can dramatically shape how much they gain. By analysing both pre- and post-test scores across multiple interventions, Nuaxia quantified how baseline competence predicts learning growth. The data reveal a clear pattern: the lower the starting knowledge, the greater the improvement, while higher baseline scores leave less room for growth. Through regression analysis and scatter plot visualisation, we show that nearly 50% of the variation in learning gains is explained by pre-test performance. These insights highlight the value of targeting educational strategies to learners’ starting points, ensuring interventions maximise growth where it’s most needed and support all learners in achieving meaningful knowledge gains. Key Findings at a Glance Lower baseline → greater growth: Learners with lower pre-test scores showed the largest increases in post-test performance. Higher baseline → smaller gains: Learners starting with higher pre-test scores had less room to improve. Baseline predicts nearly 50% of variation: Regression analysis shows R² = 0.476, meaning pre-test scores explain almost half of the differences in learning gains. Ceiling effect is evident: The higher the initial knowledge, the smaller the potential improvement — highlighting the importance of personalised learning approaches. Implication for educators: Tailoring interventions to learners’ starting points maximises growth where it’s most needed. Why These Results Matter Baseline knowledge strongly shapes learning outcomes: those starting lower show the greatest gains, while higher-performing learners have less room to improve. These results highlight the value of tailoring education to starting competence, ensuring all learners reach their full potential. By quantifying this relationship, Nuaxia provides actionable insights for optimising medical education. Methodology The analysis was based on: Pre and Post Assessment total activity score (Moore’s Level 3a, 3b and 4) X axis = Pre-Test (%), Y axis = Absolute % Increase Regression Analysis Learners’ pre- and post-assessment scores (Moore’s Levels 3a, 3b, and 4) were analysed, with the X-axis representing pre-test scores (%) and the Y-axis showing absolute percentage increase. Regression analysis quantified how baseline knowledge predicts learning gains, highlighting the relationship between starting competence and improvement. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. For organisations planning a new CME programme or aiming to measure the impact of existing initiatives, Nuaxia’s database and analytics capabilities can help deliver meaningful outcomes. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Role of Starting Knowledge in Shaping Competency Growth Medical education builds on what learners already know, and starting knowledge can shape how much they gain. Nuaxia analysed pre- and post-test scores across Moore’s Levels 3a, 3b, and 4 to see how baseline competence drives learning growth. The pattern is clear: learners with lower starting knowledge, especially at Level 3a, make the biggest gains, while those starting higher improve less. Even across different levels, the trend holds. Which means that baseline knowledge is a strong guide to where educational effort will have the most impact. By visualising this relationship, Nuaxia shows how understanding learners’ starting points lets educators target interventions to maximise growth and meaningful knowledge gains across all Moore’s Levels. Key Findings at a Glance Lower baseline → greater growth: Learners in Moore’s Level 3a, with the lowest pre-test scores, showed the largest increases in post-test performance. Moderate baseline → steady gains: Level 3b learners started higher and still made substantial improvements, though smaller than 3a. Higher baseline → smaller gains: Level 4 learners, starting with the highest pre-test scores, had the least room to improve. Baseline predicts nearly 50% of variation: Regression analysis shows R² values around 0.47–0.56 across levels, meaning pre-test scores explain almost half of the differences in learning gains. Ceiling effect is evident: The higher the initial knowledge, the smaller the potential improvement, highlighting the importance of personalised learning approaches. Implication for educators: Tailoring interventions to learners’ starting points maximises growth where it is most needed and supports meaningful learning across all Moore’s Levels. Why These Results Matter These results show that baseline knowledge is a powerful predictor of learning gains across Moore’s Levels. By understanding where learners start, educators can design targeted interventions that maximise growth. In doing so, it ensures resources are focused where they will have the greatest impact and help all learners achieve meaningful knowledge and competency improvements. Methodology The analysis was based on: Pre and Post Assessment total activity score (Moore’s Level 3a, 3b and 4) X axis = Pre-Test (%), Y axis = Absolute % Increase Regression Analysis Learners’ pre- and post-assessment scores (Moore’s Levels 3a, 3b, and 4) were analysed, with the X-axis representing pre-test scores (%) and the Y-axis showing absolute percentage increase. Regression analysis quantified how baseline knowledge predicts learning gains, highlighting the relationship between starting competence and improvement. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. By using baseline knowledge to guide interventions, educators can personalise learning experiences, maximise impact, and ensure that learners at all Moore’s Levels achieve meaningful gains. Nuaxia’s analytics capabilities make it easier to measure, understand, and optimise educational outcomes for future programmes. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

In the fast-evolving world of healthcare, continuous medical education (CME) is vital. But how effective is it really? At nuaxia, we analysed tens of thousands of behavioural data points across over 350 global medical education activities, and the results are clear: high-quality education is making a measurable difference. The Power of Data in Understanding Medical Education Outcomes Using advanced data science techniques, including silhouette scoring and participant clustering, nuaxia evaluated the knowledge and competence changes amongst healthcare professionals (HCPs) before and after medical education interventions. With a large dataset spanning 170 specialisms in over 50 countries, this analysis provides robust, objective evidence of educational impact. Key Findings at a Glance 94% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 74% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 74% improved 23% remained stable Only 3% saw a decrease This shift underlines how well-structured education meets HCPs where they are and helps them grow, regardless of the starting point. 44% Achieved the Top Score After Medical Education Activity Perhaps most impressively, nearly half of all participants reached the top performance group, indicating that CME activities are not only raising the bar but also helping HCPs reach it. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (45.3%) or High (41.1%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (42.9%) or Top (43.5%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This benefits not only HCPs but ultimately improves patient outcomes on a global scale. Our Methodology The analysis was based on: 350+ educational activities 10 therapeutic areas 170+ medical specialties 50+ countries Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com